| INTRODUCTION
Cutaneous squamous cell carcinoma (cSCC) is the most common malignancy in solid organ transplant recipients (OTRs), followed by basal cell carcinoma (BCC).
1,2 The incidence of cSCC and BCC increases with duration of immunosuppressive therapy. 1 Important risk factors are male sex, increasing age, fair skin type, sun exposure, and smoking.
3 cSCCs are usually preceded by multiple viral warts from human papillomavirus (HPV) infection and by actinic keratoses, which also often contain HPV.
3
The virome component of the human microbiome is known to play an important role in disease, 4, 5 and HPV is particularly prevalent in the normal skin virome. 6, 7 HPVs are double-stranded DNA viruses that are classified into 5 genera (α, β, γ, μ, and ν). 8, 9 αHPVs (eg, mucosal HPV types 16 and 18) are responsible for the development of cervical carcinoma and other mucosal SCCs, including anogenital and oropharyngeal carcinomas. 10 The role of skin βPVs in cSCC carcinogenesis is controversial, 9, 11, 12 but evidence for etiologic involvement is accumulating. [13] [14] [15] [16] [17] βPV cause latent, persistent skin infections 18 and were first discovered in cSCCs from patients with epidermodysplasia verruciformis, a rare genetic skin disease characterized by increased susceptibility to βPV with a high risk of cSCC on sun-exposed skin. βPVs are ubiquitous, with more than 90% of people carrying these viruses as part of their normal skin virome. 7, 19, 20 Hair follicles are the likely reservoir. 18 βPV-infected cells may have impaired DNA repair and decreased sensitivity to apoptosis induced by ultraviolet radiation (UVR), facilitating escape from normal cellular defense mechanisms.
9,13
A substantial body of epidemiologic data show an association between HPV infection and cSCC, 12, [20] [21] [22] [23] [24] in particular, in OTRs. 25, 26 In most studies, HPV infection has been determined by detection of serologic responses to a large series of βPV and sometimes γPV types 12, [21] [22] [23] [25] [26] [27] [28] [29] [30] [31] and less frequently by detecting genomic DNA from 1 or multiple HPV types in eyebrow hair or skin scrapings. 20, 21, 25, [32] [33] [34] Case-control studies in both OTR and immunocompetent populations have shown that the presence of βPV DNA or antibodies was associated with a 1.5-to 3-fold increased risk of cSCC. 12, [20] [21] [22] [23] [24] [25] [26] 29, 31, 32 It was not possible, however, to determine whether the βPV infection increases risk of cSCC development or whether cSCC formation promotes active proliferation of βPV. To our best knowledge, there is only 1 published cohort study in OTRs that investigated the influence of βPV infection on the development of cSCC. 26 In a single-center study in 445 patients, OTRs who were βPV seropositive around the time of transplantation had an almost 3-fold increased risk of developing cSCC during the 22-year follow-up period. 26 There are no prospective studies in which the associations between cSCC and both the number and DNA load of βPV types have been examined.
In this study, we present data from 2 prospective multicenter cohort studies confirming that the presence of human skin βPV infection is associated with cSCC development in OTRs.
| METHODS

| Participants and study design
As part of a European Union-funded fifth framework program (5FP) collaborative research grant (QLK2-CT-2002-0117), the EPI-HPV-UV-CA study group collected data for a prospective 35 25, 32, [35] [36] [37] [38] In cohort 1, eyebrow hair and serum were collected at 1, 3, 6, 9, 
| Statistical analysis
Cohorts 1 and 2 were analyzed separately and in combination. To estimate the independent effect of risk factors on the occurrence of cSCC or BCC, a Cox model was used. Second and subsequent cSCCs or BCCs were not considered, because these data were not collected.
The starting date for analysis was the day of transplantation; the end dates for those not diagnosed with cSCC or BCC were the end of follow-up or death. Proportionality of the hazard was assessed by plotting Schoenfeld residuals for relevant covariates and by introducing interactions of relevant covariates with time in the Cox model. A value of P < .05 indicated a violation of the proportionality assumption.
A competing risk model with death as competing event and delayed entry (also referred to as left truncation) was used to estimate the cumulative incidence of first cSCC or BCC since transplantation. 39, 40 Competing risk models take into account situations where more than 1 cause of failure is possible. In our study, the 2 competing events were cSCC or BCC and death, as patients might have died beforethe occurrence of cSCC or BCC. Delayed entry was used to adjust for the fact that in cohort 2 the HPV DNA testing and serology were not performed at the time of transplantation and that we had taken the 12-month time point in cohort 1.
We had previously defined a new variable based on concordance of βPV DNA and serology. We classified OTR according to whether they were both antibody and DNA positive for the same βPV type as follows: antibody negative, regardless of DNA status; antibody positive but with no types for which DNA was also found; and antibody positive with at least 1 type concordant for DNA. 25 The final analyses were adjusted for sex, age, skin type, and study center (study center being an important composite variable representing differences in patient populations, immunosuppression regimens, and sun exposure between the 3 clinical sites). We also investigated the other clinical variables, and none changed the estimates of interest. These were, therefore, not included in the analysis. Analyses of cohort 2 or of the combined cohorts showed that adjustment for type of immunosuppression, type of organ transplanted, average sun exposure, number of sunburns, smoking, or alcohol consumption did not substantially change the hazard ratios (HRs) (data not shown). We did not adjust for keratotic skin lesions and common viral warts, as these potentially lie on the causal pathway between HPV infection and cSCC or BCC and their inclusion in the model may lead to overadjustment, biasing the result toward the null. 41 The analyses concerning the competing risk model were performed in R environment (http://www.R-project.org) with the mstate library. 42 All other analyses were performed with SPSS Statistics for Windows version 23.0 (IBM Corp., Armonk, NY).
| RESULTS
The median and maximum follow-up times since transplantation were 9.5 and 12.4 years in cohort 1 and 18.7 and 29.9 years in cohort 2, respectively. The median and maximum follow-up times since DNA and serum sampling did not differ between the cohorts and were 9. mofetil in combination with tacrolimus, rather than azathioprine, which was the main immunosuppressive drug in cohort 2. The numbers of keratotic lesions and common viral warts were higher in cohort 2, consistent with their longer duration of immunosuppression (Table 1) . Table 2 shows the cause-specific HRs for prognostic factors associated with cSCC in the 2 cohorts combined. Results generated from individual cohort analyses are comparable (Tables S1 and S2 ).
Male sex, increasing age, fair skin type, and immunosuppression with azathioprine were the strongest risk factors for cSCC. Because the The P-values refer to the differences between cohorts 1 and 2 and are calculated with a χ 2 test (ordinal data) or ANOVA (continuous data).
Significant P-values are indicated in bold. Aza, azathioprine; CyA, cyclosporin A; MMF, mycophenolate mofetil; Tac, tacrolimus.
T After adjustment, sun exposure, painful sunburns, and smoking were not associated with cSCC in the combined cohort ( Table 2 ).
The number of βPV types in eyebrow hair, βPV DNA load, and serologic responses to HPV did not significantly differ between the 2 cohorts (Table 1 ). Figure 1 Table 3 reports the association between presence of βPV DNA in eyebrow hair and subsequent development of cSCC. The combined adjusted HR was 1.7 (95% CI 1.1-2.6). More detailed information is provided in the Tables S3-S5 .
High βPV load was also associated with a significantly higher cumulative incidence of cSCC compared with a low load or absent βPV types ( Figure 1B and Table 3 ). In the combined cohort, the adjusted HR was 1.8 (95% CI 1.2-2.8). The βPV load risk factor in cohort 1 was probably driving the HRs in the combined analyses.
HPV seropositivity at the time of sampling was not associated with cSCC risk ( Figures 1C and 1D and Table 3 ). The association was stronger but still not significant for concordant serologic responses ( Figure 1D and Table 3 ). We observed a weak association between γPV seropositivity and cSCC (Table 3 ) but no association with αPV, μPV, and νPV seropositivity (Tables S3-S5) . We examined possible heterogeneity of βPV effects between cohorts 1 and 2, but this was not the case in the univariate and adjusted analyses for any of the variables in Table 3 . We were unable to assess the influence of type of organ transplanted because our study populations were mostly kidney transplant recipients. There was no evidence of violation of the proportional hazard assumption.
Data on individual HPV types suggested that βPV of species 1, specifically HPV types 5, 8, 20, 21 , and 36, are those most likely to be involved in cutaneous squamous carcinogenesis, with possible roles for HPV76 (species 3) and HPV92 (species 4) ( Table S6 ). The increased risk of skin cancer was specific for cSCC; there were no statistically significant associations between HPV infection and the development of BCC (Table S7 ).
| DISCUSSION
In this observational hospital-based study of 2 OTR cohorts with a follow-up period after HPV sampling of longer than 10 years, we found that the diversity and load of infecting βPV types were associated with an approximately doubled risk of cSCC. Our results were robust after adjustment for multiple potential confounders. This level of increased risk is equivalent to that associated with other well-established risk factors such as skin phototype 3 and points to an important role for the skin virome and specifically HPV in the pathogenesis of cSCC.
HPV constitute an important part of the normal human skin virome. 6, 7, 19, 20 There is strong evidence from laboratory studies to suggest 
All hazard ratios (HRs) are calculated using delayed entry and adjusting for competitive risk of death. Significant HRs are indicated in bold. Aza, azathioprine; CyA, cyclosporin A; MMF, mycophenolate mofetil; SCC, squamous cell carcinoma; Tac, tacrolimus.
a
The adjusted HRs are calculated with the factor of interest and sex, age at physical examination, skin type, and study center included in the model. E6/E7 transgenic mice, UVR also induced the development of actinic keratoses and cSCC. 17 Certain βPV types also appear to have enhanced replication in the context of host immunosuppression, likely accompanied by increased oncogene expression and oncogenic activity. 44 Previous epidemiologic studies investigating the association between βPV and cutaneous squamous carcinogenesis have generated inconsistent findings. 9, 11, 12 One of the challenges is the diversity of recognized HPV types within the normal skin virome. 33, 34 More than 200 HPV types have been identified, and the number of putative new types is increasing. 33, 34, 45 We tested for only a subset of HPV types. Our polymerase chain reaction-based βPV DNA detection technique was state-of-theart when we initiated this study and remains a reliable and reproducible method. It is possible, however, that the true association between βPV infection and cSCC is even stronger, as we may have failed to detect additional relevant HPV infections. We also observed that seropositivity to γPV was associated with subsequent cSCC, supporting recent findings that γPV type HPV197 is commonly present in skin tumors 34 and that its E6 and E7 proteins interact with a set of cellular proteins similar to those encoded by genital HPVs linked to human carcinogenesis. 45 Another limitation of this study was the lack of follow-up data in Berlin and Verona. While this decreased the power of the study, we believe that it is unlikely to have introduced bias because all patients in these 2 centers were excluded, independent of their medical history.
Although cohort 1 was ideally designed for analysis of the involvement of HPV in cSCC development, we were hampered by the low number of events during the first 10 years after transplantation. Therefore, cohorts 1 and 2 were combined, which in the crude associations between the presence, number, and load of βPV DNA with the later development of cSCC appeared similar. There were also differences between the 2 cohorts. In recent years, older patients were more frequently transplanted, the immunosuppressive regimen changed, and a larger proportion of patients with a darker skin phototype were transplanted, especially in Leiden and London.
Other potential limitations of this study are missing data in the clinical characteristics included in the multivariable analyses. Of T A B L E 3 Risk of cutaneous squamous cell carcinoma in organ transplant recipients with human papillomavirus infection according to the presence of βPV DNA and/or serologic response to βPV 
4)
All hazard ratios (HRs) are calculated using delayed entry and adjusting for competitive risk of death. Significant HRs are indicated in bold.
a
The detailed numbers of squamous cell carcinoma per cohort and per exposure are provided in the supplementary material (Tables S3-S5 ).
b Adjusted HRs are not available for cohort 1 because of low number of events. c The HRs are adjusted for sex, age at physical examination, skin type, and study center. particular concern is the 28% missing data for alcohol consumption, but we found no evidence that adjusting for alcohol in those with complete information made any difference to the estimates of association between HPV and cSCC. We have no good explanation why we did not find a statistically significant association with βPV serology. We have shown a 40% increased risk of cSCC overall in seropositive OTRs but had to exclude a substantial number of patients because of missing data, decreasing the power of our study, which may be a possible explanation of our failure to show a statistically significant association between βPV serology and cSCC.
This cohort study provides evidence that infection with βPV is associated with the development of cSCC. βPV vaccines are now in development, and our data provide a rationale for routine pretrans- 
